MedCity News on LinkedIn: Johnson & Johnson’s Proteologix acquisition adds a pipeline of bispecific… (2024)

An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis:-•The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis.•However, these large proteins must be administered by injection.•JNJ-77242113 is a novel, orally administered interleukin-23–receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.•#mabs #cytokines #interleukin

18

The first patient has been dosed in Artax Biopharma Inc’s Phase 2a trial evaluating the safety and biomarker responses of AX-158 in a first proof-of-mechanism trial in #psoriasis. AX-158, a Nck blocker, acts by selectively targeting Nck function and recalibrating T-cell receptor responses. It has the broad potential totreat many #autoimmunediseases without causing immunosuppression. Safety and efficacy results from this study will be availablein the second half of 2024. #autoimmune #autoimmuneawareness

1

TL1A is a high-value target with implications across several auto-immune inflammatory diseases, including ulcerative colitis and Crohn’s disease. In October 2023, Roche (SIX:ROG) agreed to acquire rights toRVT-3101, Roivant Sciences’ (NASDAQ:ROIV) TL1A-targeting antibody, for $7.1 billion upfront and $150 million in upcoming milestone payments. Visible Alpha consensus estimates for RVT-3101 project peak global revenues of nearly $2.5 billion in 2032 (not adjusted for risk).https://lnkd.in/dGEHCxSs

7

Some updated data from DESTINY-Lung02 shows around 1 in 10 patients will get interstitial lung disease at the 5.4 mg/kg dose, and around 3 in 10 patients will get interstitial lung disease at the 6.4 mg/kg dose. This lines up with the reported rates of ILD in other studies. Trastuzumab deruxtecan is a great drug, but ILD remains one of the major hurdles in administering this drug to patients. Multiple antibody drug conjugates have had difficulties finding the correct dose, and it is still an open question as to whether an even lower dose would have lower rates of ILD with similar efficacy. #enhertuhttps://lnkd.in/gut8nvJN

3

New!#SHIKARI®#ELISAKIT for quantitative measurement anti-drug antiboides to#Risankizumab.By mesuring the levels of ADA to Risankizumab disease progression can be followed.https://lnkd.in/duAqv_Wp Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for #interleukin23 (IL-23). As an interleukin-23 antagonist, Risankizumab used to treat moderate to severe plaque #psoriasis, active psoriatic #arthritis, and moderately to severely active #Crohns disease in adults.

11

Small molecule PCSK9 Inhibitors and methods of use thereof for the treatment of cardiovascular diseasesWO 2024/013209With so many Statins around what makes PCSK9 the poster child of modern drug discovery?Statins actually actually upregulate PCSK9 in HepG2 cells and in human primary hepatocytes through the increased expression of SREBP-2, a transcription factor that upregulates both the LDLR and PCSK9 genes. Now since an elevated levels of PCSK9 decreases the abundance of LDL receptor on the cell surface, increasing doses of statins have failed to achieve proportional LDL-cholesterol lowering effects.https://lnkd.in/daZnbK8m

39

1 Comment

IL-2 is small 15-kDa cytokine with diverse effects on the immune system.✔️IL-2 Receptors: 1️⃣ Trimeric IL-2 Receptor (IL-2R):Components: IL-2Rα (CD25), IL-2Rβ (CD122), and CD132 (common gamma chain).Mainly found on immunosuppressive regulatory T (Treg) cells.High affinity for IL-2 (10–100 times higher than dimeric IL-2Rs). 2️⃣Dimeric IL-2 Receptor (IL-2R): Composed of CD122 and CD132. Present on resting antigen-experienced (memory) effector T (Teff) and natural killer (NK) cells.This paper reviews clinical results of improved IL-2-based compounds.https://lnkd.in/gkaPbnvG

25

4 Comments

Advancements in Migraine Treatment: What You Need to KnowAfter analyzing 74 trials involving 32,990 patients, it's clear💡: monoclonal antibodies targeting CGRP or its receptor, gepants, and topiramate stand out in significantly reducing monthly migraine🧠 days by 50% or more compared to placebo. While beta-blockers, valproate, and amitriptyline show moderate efficacy, they also pose higher risks of adverse events leading to discontinuation. The verdict is in: (CGRP(r)mAbs) emerge as the champions of migraine prophylaxis, with gepants closely trailing behind. It's time to prioritize safety and efficacy in migraine management. #MigraineRelief #BreakthroughTreatmenthttps://lnkd.in/e_m2zRsK

5

This new research article in #JIPO by Ebinama et al. discusses pulmonary immune-related adverse events of PD1 versus PDL-1 checkpoint Inhibitorshttps://lnkd.in/dkPuCMtr#ROR #AdverseEvents

How do I design my peptide library or pool?Learn more: https://bit.ly/42VPgX1#myjpt #peptideabc #immunotherapy#immunooncology#peptidetools#cancerresearch#custompeptides#tcells

8

2 Comments